摘要
目的探讨比克恩丙诺片与一线ART抗病毒治疗人类免疫缺陷病毒(HIV)/获得性免疫缺陷综合征(AIDS)的效果评价。方法前瞻性选取2020年3月至2022年3月在广西来宾市人民医院诊治的82例HIV/AIDS患者作为研究对象,按照随机数字表法将其分为观察组与对照组,每组各41例。观察组给予比克恩丙诺片治疗,对照组给予一线ART抗病毒治疗。比较两组患者的T淋巴细胞亚群(CD4^(+)、CD8^(+)、CD4^(+)CD45RA^(+))、HIV RNA定量、白细胞介素(IL)-17、IL-23、免疫重建成功率及不良反应发生率。结果治疗后,两组CD4^(+)、CD8^(+)、CD4^(+)CD45RA^(+)均较治疗前明显升高,且观察组CD4^(+)、CD8^(+)、CD4^(+)CD45RA^(+)均高于对照组,差异均有统计学意义(P<0.05)。治疗后,两组HIV RNA定量较治疗前明显降低,且观察组的HIV RNA定量低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组的IL-17、IL-23水平均较治疗前升高,且观察组的IL-17、IL-23水平均高于对照组,差异均有统计学意义(P<0.05)。观察组免疫重建成功率为73.17%,高于对照组(51.22%),差异有统计学意义(P<0.05)。观察组不良反应总发生率为7.32%,低于对照组(24.39%),差异有统计学意义(P<0.05)。结论比克恩丙诺片治疗HIV/AIDS效果优于一线ART抗病毒,不仅能更好地调整患者机体免疫,并且能降低HIV RNA定量,且安全性高,无严重不良反应。
Objective To evaluate the efficacy of Biktarvy and first-line ART antiviral therapy in the treatment of human immunodeficiency virus(HIV)/acquired immunodeficiency syndrome(AIDS).Methods A total of 82 HIV/AIDS patients diagnosed and treated in Laibin Municipal People's Hospital from March 2020 to March 2022 were prospectively selected as research objects.According to random number table method,they were divided into observation group and control group,with 41 cases in each group.The observation group received Biktarvy treatment,and the control group received first-line ART antiviral treatment.T lymphocyte subsets(CD4^(+),CD8^(+),CD4^(+)CD45RA^(+)),HIV RNA quantition,interleukin(IL)-17,IL-23,success rate of immune reestablishment and incidence of adverse reactions of the two groups were compared.Results After treatment,the levels of CD4^(+),CD8^(+),CD4^(+)CD45RA^(+)in two groups were significantly higher than those before treatment,and the levels of CD4^(+),CD8^(+),CD4^(+)CD45RA^(+)in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).After treatment,the HIV RNA quantification in the two groups was significantly lower than those before treatment,and the HIV RNA quantification in the observation group was lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of IL-17 and IL-23 in two groups were significantly higher than those before treatment,and the levels of IL-17 and IL-23 in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).The success rate of immune reconstruction in the observation group was 73.17%,higher than that in the control group(51.22%),the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 7.32%,lower than that in the control group(24.39%),the difference was statistically significant(P<0.05).Conclusion The efficacy of Biktarvy in the treatment of HIV/AIDS is better than that of first-line ART antiviral,which not only can better adjust the immune system of patients,but also can reduce the amount of HIV RNA,with high safety and no serious adverse reactions.
作者
周巧玉
莫金荣
廖炯
覃舒扬
李春红
韦珠梅
黄晓娟
ZHOU Qiao-yu;MO Jin-rong;LIAO Jiong(Department of Infectious Diseases,Laibin Municipal People's Hospital,Laibin Guangxi 546100,China)
出处
《临床和实验医学杂志》
2023年第20期2168-2171,共4页
Journal of Clinical and Experimental Medicine
基金
广西壮族自治区卫生健康委项目(编号:Z20201026)
来宾市科学研究与技术开发计划项目(编号:来科转202422)。
